valproic acid has been researched along with palbociclib in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Booth, L; Cutler, RE; Dent, P; Diala, I; Lalani, AS; Poklepovic, A; Rais, R; Roberts, JL | 1 |
1 other study(ies) available for valproic acid and palbociclib
| Article | Year |
|---|---|
Palbociclib augments Neratinib killing of tumor cells that is further enhanced by HDAC inhibition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Female; Histone Deacetylase Inhibitors; Humans; Mice; Ovarian Neoplasms; Piperazines; Pyridines; Quinolines; Valproic Acid; Xenograft Model Antitumor Assays | 2019 |